This announcement is a separate document:
JCRファーマ：「テムセルHS注」の新生児低酸素性虚血性脳症に対する適応拡大（開発番号：JR-031HIE）開発中止のお知らせ
JCR Pharmaceuticals: Announcements of individual stocks: Development of "Temcell HS injection" for neonatal hypoxic ischemic encephalopathy has been discontinued for expansion of indication (development code: JR-031HIE).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.